| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/16/2003 | US20030012767 Tissue-specific taanscriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said vector. |
| 01/16/2003 | US20030012325 Mixture containing rare earth and the use thereof |
| 01/16/2003 | CA2453098A1 Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452835A1 Aromatic sulfenates for type i phototherapy |
| 01/16/2003 | CA2452609A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | CA2452603A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | CA2452592A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | CA2452501A1 Secreted proteins |
| 01/16/2003 | CA2452366A1 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | CA2451738A1 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine |
| 01/16/2003 | CA2451395A1 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | CA2451055A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | CA2450502A1 Epf receptor assays, compounds and therapeutic compositions |
| 01/16/2003 | CA2450236A1 Phage displayed pdz domain ligands |
| 01/16/2003 | CA2449828A1 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/15/2003 | EP1275965A1 Method for identifying substances which modulate interleukin 4 (IL-4) signaling |
| 01/15/2003 | EP1275724A1 Bonding reagents for cell surface protein and effector cells |
| 01/15/2003 | EP1275635A1 Calcium receptor-active compounds |
| 01/15/2003 | EP1275400A1 Therapeutic composition of non MHC-restricted T-cells/NK-cells and MHC-restricted cells for the treatment of tumors |
| 01/15/2003 | EP1275393A1 Pharmaceutical formulation containing pteridine derivative |
| 01/15/2003 | EP1275389A1 Compositions containing C7 Taxanes |
| 01/15/2003 | EP1275382A2 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
| 01/15/2003 | EP1275377A1 Granulates containing liposoluble substances and process of preparation thereof |
| 01/15/2003 | EP1274980A1 Solution and crystal structures of mmp-13 active site and uses thereof |
| 01/15/2003 | EP1274866A2 Diagnosis of diseases associated with metastasis |
| 01/15/2003 | EP1274865A2 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 01/15/2003 | EP1274861A1 Compositions and methods for identifying and targeting cancer cells |
| 01/15/2003 | EP1274851A1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274842A2 Lipid binding protein 4 |
| 01/15/2003 | EP1274841A2 Regulation of human cyslt2-like gpcr protein |
| 01/15/2003 | EP1274840A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 01/15/2003 | EP1274835A1 Human nim1 kinase |
| 01/15/2003 | EP1274834A1 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 01/15/2003 | EP1274731A1 Human hepatocyte growth factor activator inhibitor homologue |
| 01/15/2003 | EP1274730A2 Integrin/adhesion antagonists |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274706A1 Pyrazoles for inhibiting protein kinases |
| 01/15/2003 | EP1274705A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| 01/15/2003 | EP1274700A1 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders |
| 01/15/2003 | EP1274697A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 01/15/2003 | EP1274694A1 Novel compounds |
| 01/15/2003 | EP1274692A1 Quinazoline compounds |
| 01/15/2003 | EP1274691A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors |
| 01/15/2003 | EP1274676A2 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| 01/15/2003 | EP1274458A2 Compositions containing a naphthalmide and an antiproliferative agent |
| 01/15/2003 | EP1274450A2 Cytokine uses; compositions; methods |
| 01/15/2003 | EP1274446A1 Polysaccharidic esters of n-derivatives of glutamic acid |
| 01/15/2003 | EP1274445A2 Use of steroidal alkaloids to reverse multidrug resistance |
| 01/15/2003 | EP1274431A1 10,11-difluoromethylenedioxycamptothecin compounds with topoisomerase i inhibition |
| 01/15/2003 | EP1274428A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274424A1 Compounds and methods |
| 01/15/2003 | EP1274422A1 Method for treating cells resistant to antineoplastic agents |
| 01/15/2003 | EP1274415A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274413A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274410A2 Use of locally applied dna fragments |
| 01/15/2003 | EP1274409A2 Antiprogestins with partial agonist activity |
| 01/15/2003 | EP1274408A2 Use of natural chrysanthone compounds having antiangiogenic activity |
| 01/15/2003 | EP1274407A2 Uses of ppar-gamma agonists in neutrophil-induced diseases |
| 01/15/2003 | EP1274404A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
| 01/15/2003 | EP1274399A1 Liposomes containing an entrapped compound in supersaturated solution |
| 01/15/2003 | EP1157105A4 Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene |
| 01/15/2003 | EP1063998B1 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 01/15/2003 | EP1062202B1 Cytostatic agents |
| 01/15/2003 | EP0979235A4 Isolated nucleic acid molecule coding for tumor rejection antigen precursors mage-c1 and mage-c2 and uses thereof |
| 01/15/2003 | EP0925287B1 Heterocyclic metalloprotease inhibitors |
| 01/15/2003 | EP0912572B1 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| 01/15/2003 | EP0749981B1 Monoclonal antibody specific for pd-ecgf / thymidine phosphorylase |
| 01/15/2003 | EP0595796B1 Method of treatment of androgen-related diseases |
| 01/15/2003 | EP0584347B1 Enantiomeric hydroxylated xanthine compounds |
| 01/15/2003 | CN1391608A Cloning, expression and characterisation of gene expressed in tumour cells and involved in regulation of immune response |
| 01/15/2003 | CN1391577A Pharmaceutical compositions comprising metal complexes |
| 01/15/2003 | CN1391576A Androgen receptor modulator compounds and methods |
| 01/15/2003 | CN1391570A Phenyl-and pyridyl-tetrahydro-pyridines having TNF inhibiting activity |
| 01/15/2003 | CN1391563A Therapeutic quinazoline derivatives |
| 01/15/2003 | CN1391562A Quinazoline derivatives as pharmaceuticals |
| 01/15/2003 | CN1391561A Quinazoline compounds and pharmaceutical compositions containing them |
| 01/15/2003 | CN1391560A 喹唑啉衍生物 Quinazoline derivatives |
| 01/15/2003 | CN1391557A 6-position substituted indoline, production and use thereof as medicament |
| 01/15/2003 | CN1391556A IL-8 receptor antagonists |
| 01/15/2003 | CN1391487A Methods for treating therapy-resistant tumors |
| 01/15/2003 | CN1391486A Methods for treating therapy-resistant tumors |
| 01/15/2003 | CN1391484A Method of potentiating chemotherapy and treating solid tumors |
| 01/15/2003 | CN1391483A Composition of octoxinol and polyvinyl chloride sorbitanate as accessory and uses in vaccins |
| 01/15/2003 | CN1391473A VLA-4 inhibitor compounds |
| 01/15/2003 | CN1391471A Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 01/15/2003 | CN1391468A Pharmaceutical compositions comprising adenosine receptor agonist or antagonist |
| 01/15/2003 | CN1390846A Aminoglycopeptide compounds with antivirus and anticanser activity |
| 01/15/2003 | CN1390839A Composition of garcinolic acid compounds, its preparing process and medical composition using it as active component |
| 01/15/2003 | CN1390837A Anti-inflammatory and antineoplastic R-bis or glycophenylpropane isoselenazole substituted compound |
| 01/15/2003 | CN1390834A Indenoindolone compounds, their preparation and medicinal compositions containing them |
| 01/15/2003 | CN1390605A Medicine C-AEDP using C as carrier for target therapy of osteopath and its usage |
| 01/15/2003 | CN1390588A Composite medicine for treating leukemia |
| 01/15/2003 | CN1390560A Orally applied anticancer tablet |
| 01/15/2003 | CN1390551A Pharmaceutical usage of diosgenin |
| 01/15/2003 | CN1390544A Antineoplastic usage of iodated-3,3'-diethyl-9-methyl thiocarbonyl cyanine |
| 01/15/2003 | CN1390537A Medicine for preventing or treating cancer and its usage |